Results 161 to 170 of about 84,367,963 (213)
Some of the next articles are maybe not open access.
Radical-derived oxidation products of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid
Journal of Chromatography B: Biomedical Sciences and Applications, 19945-Aminosalicylic acid is an agent effective in the treatment of chronic inflammatory bowel diseases. Its ability to scavenge radicals is considered to be a major factor responsible for its therapeutic efficacy. In this study oxidation products of aminosalicylates with hydroxyl radicals were produced.
C, Fischer, U, Klotz
openaire +2 more sources
Archives of Pharmacal Research, 2003
5-Aminosalicylic acid (5-ASA) is an active ingredient of therapeutic agents used for Crohn's disease and ulcerative colitis. Because it is absorbed rapidly and extensively in the upper intestine, delivery of the agent specifically to the colon is necessary. We selected taurine as a colon-specific promoiety and designed 5-aminosalicyltaurine (5-ASA-Tau)
Yun Jin, Jung +3 more
openaire +2 more sources
5-Aminosalicylic acid (5-ASA) is an active ingredient of therapeutic agents used for Crohn's disease and ulcerative colitis. Because it is absorbed rapidly and extensively in the upper intestine, delivery of the agent specifically to the colon is necessary. We selected taurine as a colon-specific promoiety and designed 5-aminosalicyltaurine (5-ASA-Tau)
Yun Jin, Jung +3 more
openaire +2 more sources
Acta Obstetricia et Gynecologica Scandinavica, 1994
To determine the concentration of 5-aminosalicylic acid (5-ASA) and the metabolite N-acetyl-5-aminosalicylic acid (Ac-5-ASA) in the maternal and fetal plasma at delivery and in the maternal milk post partum.Pregnant and lactating women with chronic inflammatory bowel disease, treated with different pure 5-ASA preparations participated in the study.
L A, Christensen +2 more
openaire +2 more sources
To determine the concentration of 5-aminosalicylic acid (5-ASA) and the metabolite N-acetyl-5-aminosalicylic acid (Ac-5-ASA) in the maternal and fetal plasma at delivery and in the maternal milk post partum.Pregnant and lactating women with chronic inflammatory bowel disease, treated with different pure 5-ASA preparations participated in the study.
L A, Christensen +2 more
openaire +2 more sources
Inhibition of Antibody Secretion by 5-Aminosalicylic Acid
Gastroenterology, 1989We have examined the effects of sulfasalazine and its metabolites sulfapyridine and 5-aminosalicylic acid on antibody secretion by normal peripheral blood and intestinal mononuclear cells. Sulfasalazine and 5-aminosalicylic acid both inhibited pokeweed mitogen-stimulated secretion of immunoglobulins (Igs) A, G, and M by peripheral blood mononuclear ...
R P, MacDermott +5 more
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2019
Despite the emergence of new biological therapies that aim for mucosal healing as a new therapeutic target, the importance of 5-ASA formulations in the standard treatment for inflammatory bowel diseases, particularly ulcerative colitis, remains unchanged.
Tomoya, Iida +2 more
openaire +1 more source
Despite the emergence of new biological therapies that aim for mucosal healing as a new therapeutic target, the importance of 5-ASA formulations in the standard treatment for inflammatory bowel diseases, particularly ulcerative colitis, remains unchanged.
Tomoya, Iida +2 more
openaire +1 more source
Oral desensitization to 5-aminosalicylic acid medications
Annals of Allergy, Asthma & Immunology, 1999Although hypersensitive subjects have been desensitized to oral sulfasalazine, the feasibility of oral desensitization to the drug's active moiety, 5-aminosalicylic acid has been questioned and never been reported.We devised a 5-aminosalicylic acid desensitization protocol and administered the drug to two hypersensitive subjects on three occasions.Both
R C, Stelzle, E N, Squire
openaire +2 more sources
Possible mode of action of 5-aminosalicylic acid
Digestive Diseases and Sciences, 1987Despite the extensive use of sulfasalazine (SAS) and/or 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease and, more recently, rheumatoid arthritis, their mode of action has not been elucidated so far. None of the numerous pharmacological and biochemical effects described, including immunosuppressive, antifolate, and modulatory ...
B M, Peskar +4 more
openaire +2 more sources
5-Aminosalicylic Acid and Chemoprevention: Does It Work?
Digestive Diseases, 20135-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD). Intestinal inflammation is the main risk factor for colorectal cancer (CRC) in IBD. Hence, all drugs that are able to induce and maintain mucosal healing (MH) may prevent CRC risk in IBD.
Lopez, Anthony, Peyrin-Biroulet, Laurent
openaire +2 more sources
The anti-oxidant properties of 5-aminosalicylic acid
Free Radical Biology and Medicine, 1996Oxidative damage to biological membranes is an important cause of tissue injury in inflammatory bowel disease. 5-Aminosalicylic Acid (5ASA) has therapeutic efficacy in Ulcerative colitis, which may be based on its antioxidant properties. We used Parinaric acid as a fluorescent marker of oxidation in an intestinal microvillous brush border membrane ...
D C, Pearson +2 more
openaire +2 more sources
Archives of Pharmacal Research, 1998
Dextran-5-aminosalicylic acid ester (dextran-5-ASA) was synthesized as a colon-specific prodrug of 5-aminosalicylic acid (5-ASA) which is active against inflammatory bowel diseases. Chemical stability of dextran-5-ASA in the bath of pH 1.2 or 6.8 was investigated at 37 degrees C for 6 hrs, and 5-ASA was not released on such conditions. Depolymerization
Y J, Jung +4 more
openaire +2 more sources
Dextran-5-aminosalicylic acid ester (dextran-5-ASA) was synthesized as a colon-specific prodrug of 5-aminosalicylic acid (5-ASA) which is active against inflammatory bowel diseases. Chemical stability of dextran-5-ASA in the bath of pH 1.2 or 6.8 was investigated at 37 degrees C for 6 hrs, and 5-ASA was not released on such conditions. Depolymerization
Y J, Jung +4 more
openaire +2 more sources

